Aprea Therapeutics, Inc.(APRE), a clinical-stage biopharmaceutical company, Monday announced that it has dosed a patient with HPV+ Head and Neck Squamous Cell Carcinoma or HNSCC in its ongoing ACESOT-1051 clinical trial.
This is the first patient to be dosed in Cohort 5 of the study, which involves a 70 mg once-daily dose of APR-1051, a WEE1 inhibitor.
The study is evaluating APR-1051 in patients with advanced solid tumors, including HPV+ HNSCC.
The trial aims to explore the potential of WEE1 inhibition, which targets tumor cells with high replication stress and DNA damage accumulation.
HPV-driven cancers, including HPV+ HNSCC, are particularly susceptible to this treatment due to defects in their DNA damage repair pathways.
Aprea is focusing on identifying patient populations most likely to benefit from WEE1 inhibition.
The trial is progressing well, and the company is encouraged by the safety profile of APR-1051.
The ACESOT-1051 study will also explore the optimal dose for future studies, with preliminary open-label data expected in the second half of 2025.
Additionally, Aprea recently entered into a Material Transfer Agreement or MTA with MD Anderson Cancer Center to support preclinical research on the potential of APR-1051 for treating HPV+ and HPV- HNSCC.
The trial is being conducted at multiple sites, including MD Anderson Cancer Center.
Currently, APRE is trading at $2.06 down by 0.96 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.